Patient Breathing Motion and Delivery Specifics Influencing the Robustness of a Proton Pancreas Irradiation.
4D
dose calculations
interplay
pancreatic cancer
proton therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Apr 2023
29 Apr 2023
Historique:
received:
27
02
2023
revised:
24
04
2023
accepted:
28
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Motion compensation strategies in particle therapy depend on the anatomy, motion amplitude and underlying beam delivery technology. This retrospective study on pancreas patients with small moving tumours analysed existing treatment concepts and serves as a basis for future treatment strategies for patients with larger motion amplitudes as well as the transition towards carbon ion treatments. The dose distributions of 17 hypofractionated proton treatment plans were analysed using 4D dose tracking (4DDT). The recalculation of clinical treatment plans employing robust optimisation for mitigating different organ fillings was performed on phased-based 4D computed tomography (4DCT) data considering the accelerator (pulsed scanned pencil beams delivered by a synchrotron) and the breathing-time structure. The analysis confirmed the robustness of the included treatment plans concerning the interplay of beam and organ motion. The median deterioration of
Identifiants
pubmed: 37174016
pii: cancers15092550
doi: 10.3390/cancers15092550
pmc: PMC10177445
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Gesellschaft für Forschungsförderung, Niederösterreich
ID : SC19-013
Références
Radiother Oncol. 2022 Sep;174:23-29
pubmed: 35788354
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):587-94
pubmed: 18474315
Pancreas. 2020 Jul;49(6):737-743
pubmed: 32590617
Phys Med Biol. 2019 Nov 26;64(23):235001
pubmed: 31652424
Phys Med Biol. 2018 Apr 19;63(8):085012
pubmed: 29671410
Phys Imaging Radiat Oncol. 2023 Apr 11;26:100439
pubmed: 37124167
Radiother Oncol. 2021 Apr;157:210-218
pubmed: 33545257
Phys Med Biol. 2022 Nov 02;67(21):
pubmed: 36179702
Phys Med Biol. 2018 May 02;63(9):095006
pubmed: 29616984
Radiother Oncol. 2020 Sep;150:268-274
pubmed: 32768509
Z Med Phys. 2018 Apr;28(2):121-133
pubmed: 28843397
Radiother Oncol. 2020 Jun;147:178-185
pubmed: 32380117
Z Med Phys. 2022 Feb;32(1):39-51
pubmed: 33640219
Radiother Oncol. 2022 Nov;176:208-214
pubmed: 36228759
Med Phys. 2022 Jun;49(6):3538-3549
pubmed: 35342943
Phys Med Biol. 2018 Aug 10;63(16):165005
pubmed: 30020079
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):41-50
pubmed: 28816159
Z Med Phys. 2018 Aug;28(3):196-210
pubmed: 29107440
Med Phys. 2015 Jan;42(1):40-53
pubmed: 25563246
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S94-100
pubmed: 20171524
Phys Med Biol. 2017 Oct 04;62(20):8136-8153
pubmed: 28817381
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
Front Oncol. 2022 Mar 09;12:806153
pubmed: 35356213
J ICRU. 2010 Apr;10(1):27-40
pubmed: 24173325
Phys Med Biol. 2011 Aug 21;56(16):R113-44
pubmed: 21775795
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406558
Clin Oncol (R Coll Radiol). 2020 Jul;32(7):467-476
pubmed: 32081577
Radiother Oncol. 2018 Jul;128(1):174-181
pubmed: 29571904
Clin Transl Radiat Oncol. 2022 Nov 09;38:111-116
pubmed: 36407488
Med Phys. 2022 Aug;49(8):5182-5194
pubmed: 35598307
Radiat Oncol. 2018 Jun 25;13(1):120
pubmed: 29941049
Front Oncol. 2021 Apr 29;11:621350
pubmed: 33996545
Front Oncol. 2023 Mar 02;13:1112481
pubmed: 36937392
Phys Med Biol. 2021 May 10;66(10):
pubmed: 33862616
Med Phys. 2023 Jan;50(1):465-479
pubmed: 36345808
Phys Med. 2018 Oct;54:121-130
pubmed: 30337001
Phys Med Biol. 2020 Jun 23;65(12):125015
pubmed: 32340002
Phys Med Biol. 2022 Dec 26;68(1):
pubmed: 36571234